我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

AngⅡ对人心房肌细胞膜钙通道电流的影响及替米沙坦的拮抗作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第2期
页码:
115-117
栏目:
基础研究
出版日期:
2005-03-05

文章信息/Info

Title:
Effects of AngiotensinⅡ on calcium channel current of human atrial myocytes and its antagonism by telmisartan
作者:
张殿新1; 2; 黄岚1; 王海昌2; 张荣庆2; 程何祥2; 刘兵2
1. 第三军医大学新桥医院心内科,重庆 400038；2.第四军医大学西京医院心内科,陕西 西安 710032
Author(s):
ZHANG Dianxin1; HUANG Lan1; WANG Haichang2; ZHANG Rongqing2; CHENG Hexiang2; LIU Bing2
Department of Cardiology, second hospital of Xi'an Jiaotong University, Xi′an,Shaanxi 710004, China
关键词:
血管紧张素Ⅱ; 心房肌细胞; 全细胞膜片钳; 钙通道电流; 替米沙坦
Keywords:
AngiotensinⅡ;  atrial myocyte;  whole cell patch clamp;  calcium channel current;  Telmisartan
分类号:
R541.7; R331.38
DOI:
-
文献标识码:
A
摘要:
目的 观察AngⅡ对人心房肌细胞膜钙通道电流的作用，揭示其参与房性心律失常的电生理机制，为应用AngⅡ受体拮抗剂治疗房性心律失常提供实验依据。方法 急性分离单个人心房肌细胞，采用全细胞膜片钳方法记录L型钙电流（ICaL）。实验分4组：对照组，AngⅡ（0.1 μmol/L）组，替米沙坦（0.01 μmol/L）组，AngⅡ+替米沙坦组。结果 与对照组相比，0.1 μmol/L AngⅡ组使人心房肌细胞膜ICaL峰值电流密度显著增加(12.74±1.65 vs -5.78±0.82pA/pF，P<0.05)。0.01 μmol/L替米沙坦组对人心房肌细胞膜ICaL无显著影响（-5.70±0.79 pA/pF），但可拮抗AngⅡ的作用，AngⅡ+替米沙坦组的ICaL峰值电流密度 (-7.38±0.91 pA/pF)与AngⅡ组相比有显著差异（P<0.05）。结论 AngⅡ显著增加人心房肌细胞膜ICaL峰值的电流密度。替米沙坦可拮抗AngⅡ对人心房肌细胞膜ICaL的作用。
Abstract:
AIM To observe effects of angiotensinII(AngⅡ) on calcium channel current of human atrial myocytes, to reveal mechanisms of atrial arrhythmia induced by AngⅡ, and to provide a laboratory basis for application of angiotensin II receptor antagonist to the treatment of atrial arrhythmias.METHODS Single human atrial myocyte was isolated, and conventional wholecell configuration of the patchclamp technique was used to detect membrane ICaL. The experiment comprised four groups:the control group the, AngⅡ group, the telmisartan group and the AngⅡ + telmisartan group.RESULTS Compared with the control group,AngⅡ of 0.1 μmol/L significantly increased the peak density of ICaL in the human atrial myocyte(-12.74±1.65 vs-5.78±0.82 pA/pF，P<0.05). Telmisartan of 0.01 μmol/L had no significant effect on ICaL in human atrial myocyte（-5.70±0.79 pA/pF）, but it could antagonize the effects of AngⅡ. In the AngⅡ + telmisartan group, the peak density of ICaL was (-7.38±0.91)pA/pF, which was significantly different from that of the AngⅡ group（P<0.05）.CONCLUSION AngⅡ has significant electrophysiological effects on human atrial myocytes. AngⅡ of 0.1 μmol/L can significantly increase the peak density of ICaL Telmisartan can antagonize the effects of AngⅡ on human atrial myocytes.

参考文献/References

［1］ Li D, Shinagawa K, Pang L, et al.Effects of angiotensinconverting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacinginduced congestive heart failure［J］. Circulation,2001，104(21):2608-2614.

［2］Kumagai K, Nakashima H, Urata H, et al.Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation［J］. J Am Coll Cardiol, 2003,41(12):2197-2204.

［3］ Boldt A, Wetzel U, Weigl J, et al.Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease［J］. J Am Coll Cardiol, 2003, 42(10): 1785-1792.

［4］张荣庆，梁延春，周更须，等. 国人单个心房肌细胞的分离及活性鉴定［J］. 第四军医大学学报,2001，22（2）：188-190.

［5］Madrid AH, Bueno MG, Rebollo JM,et al.Use of irbesartan to maintain sinus rhythm in patients with longlasting persistent atrial fibrillation: a prospective and randomized study［J］.Circulation, 2002,106(3):331-336.

［6］吴书林，薛玉梅，钱卫民，等. 心房颤动患者心房肌细胞离子重塑及缬沙坦的干预研究［J］. 中华心血管病杂志,2004，32（3）：197-201.

［7］Ichiyanagi O, Ishii K, Endoh M.Angiotensin II increases Ltype Ca2+ current in gramicidin Dperforated adult rabbit ventricular myocytes: comparison with conventional patchclamp method［J］. Pflugers Arch, 2002,444(12):107-116.

［8］Aiello EA, Cingolani HE.Angiotensin II stimulates cardiac Ltype Ca2+ current by a Ca2+ and protein kinase Cdependent mechanism［J］. Am J Physiol Heart Circ Physiol, 2001,280(4):H1528-H1536.

［9］Maillard MP,Perregaux C,Centeno C,et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist［J］. Pharmacol,2002， 302(3): 1089-1095.

［10］Unger T.The ongoing telmisartan alone and in combination with ramipril global endpoint trial program［J］. Am J Cardiol,2003，91(10A):28G-34G.

备注/Memo

备注/Memo:
收稿日期：2004-09-20.
更新日期/Last Update: 2010-01-05